Literature DB >> 744101

Prolactin release by vasoactive intestinal polypeptide in rats.

Y Kato, Y Iwasaki, J Iwasaki, H Abe, N Yanaihara, H Imura.   

Abstract

Synthetic vasoactive intestinal polypeptide (VIP) administered either intraventricularly or iv caused a significant and dose-related increase in plasma PRL levels in urethane-anesthetized rats. The administration of naloxone, an opiate receptor antagonist, significantly blunted the plasma PRL response to VIP. Increases in plasma PRL induced by VIP were also significantly suppressed by L-dopa, a precursor of dopamine, whereas pilocarpine, a cholinergic agonist, diphenhydramine, a histamine antagonist, and cyproheptadine, an antiserotoninergic agent, did not affect the plasma PRL response to VIP. In in vitro experiments, VIP alone did not stimulate PRL release from cultured pituitary cells, but it significantly attenuated the inhibitory action of dopamine, which was not blocked by naloxone. These results suggest that VIP stimulates rat PRL secretion, at least in part, through activation of an opiate receptor in the central nervous system and by blocking the inhibitory action of a dopaminergic mechanism at the pituitary level.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 744101     DOI: 10.1210/endo-103-2-554

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  27 in total

Review 1.  Thyroid hormones and growth hormone secretion.

Authors:  R Valcavi; M Zini; I Portioli
Journal:  J Endocrinol Invest       Date:  1992-04       Impact factor: 4.256

2.  Vasoactive intestinal peptide in the human pituitary gland and adenomas. An immunocytochemical study.

Authors:  D W Hsu; P N Riskind; E T Hedley-Whyte
Journal:  Am J Pathol       Date:  1989-08       Impact factor: 4.307

3.  Immunohistochemical localization of vasoactive intestinal peptide (VIP) in the circumventricular organs of the rat.

Authors:  J D Mikkelsen
Journal:  Cell Tissue Res       Date:  1989-02       Impact factor: 5.249

4.  Vasoactive intestinal polypeptide stimulates prolactin release in vivo in the ring dove (Streptopelia risoria).

Authors:  R W Lea; D M Vowles
Journal:  Experientia       Date:  1986-04-15

5.  Coexpression of opsin- and VIP-like-immunoreactivity in CSF-contacting neurons of the avian brain.

Authors:  R Silver; P Witkovsky; P Horvath; V Alones; C J Barnstable; M N Lehman
Journal:  Cell Tissue Res       Date:  1988-07       Impact factor: 5.249

Review 6.  The pathogenic role of the GIP/GIPR axis in human endocrine tumors: emerging clinical mechanisms beyond diabetes.

Authors:  Daniela Regazzo; Mattia Barbot; Carla Scaroni; Nora Albiger; Gianluca Occhi
Journal:  Rev Endocr Metab Disord       Date:  2020-03       Impact factor: 6.514

7.  Peptidylglycine alpha-amidating monooxygenase (PAM) immunoreactivity and messenger RNA in human pituitary and increased expression in pituitary tumours.

Authors:  J H Steel; A Martínez; D R Springall; A M Treston; F Cuttitta; J M Polak
Journal:  Cell Tissue Res       Date:  1994-04       Impact factor: 5.249

8.  The Role of VIP in Social Behavior: Neural Hotspots for the Modulation of Affiliation, Aggression, and Parental Care.

Authors:  Marcy A Kingsbury; Leah C Wilson
Journal:  Integr Comp Biol       Date:  2016-12       Impact factor: 3.326

9.  The PHI (PHI-27)/corticotropin-releasing factor/enkephalin immunoreactive hypothalamic neuron: possible morphological basis for integrated control of prolactin, corticotropin, and growth hormone secretion.

Authors:  T Hökfelt; J Fahrenkrug; K Tatemoto; V Mutt; S Werner; A L Hulting; L Terenius; K J Chang
Journal:  Proc Natl Acad Sci U S A       Date:  1983-02       Impact factor: 11.205

10.  Pituitary adenylate-cyclase-activating polypeptide (PACAP) binding sites and PACAP/vasoactive intestinal polypeptide receptor expression in human pituitary adenomas.

Authors:  H Oka; L Jin; J C Reubi; X Qian; B W Scheithauer; K Fujii; T Kameya; R V Lloyd
Journal:  Am J Pathol       Date:  1998-12       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.